SPRED1’s loss of heterozygosity is thought to play a role in pediatric acute myeloblastic leukemia; furthermore, there is some evidence that Legius syndrome is possibly associated with an increased risk for kidney tumors and lung cancers [17–19]. Here, SPRED1 is linked to Legius syndrome.